MIRM

96.1800.70%
MG

Michael G. Grey

Independent Non-Executive Chairman of the Board

Mr. Michael G. Grey, also known as Mike, is Board Chair of Altay Therapeutics Inc. from 2025. He serves as Non-Employee Director of OnKure Therapeutics, Inc. from October 04, 2024. Mr. Grey is Executive Chairman of Theolytics Limited since March 2024. He serves as Executive Chairman at Plexium, Inc. since January 2021. He serves as the Chief Executive Officer and President of SGX Pharmaceuticals, Inc. Mr. Grey has been an Executive Chairman at Spruce Biosciences, Inc. since April 2017 and served as its Interim Chief Executive Officer since November 15, 2021 till January 2021. Mr. Grey has served as Independent Non-Executive Chairman of the Board at Mirum Pharmaceuticals, Inc. since January 1, 2020 and as its Independent Director since May 2018. He served as Executive Chairman of Mirum Pharmaceuticals, Inc. from March 12, 2019 to December 2019 and served as its Chief Executive Officer from May 2018 to March 2019. He also served as Chief Executive Officer and President at Curzion Pharmaceuticals, Inc. from January 2019 to September 2019. He has served as Chairman of Plexium, Inc., since August 2020. He has served as Chairman of Sorriso Pharmaceuticals, Inc since May 2021. Mr. Grey serves as a Director of Sorriso Pharmaceuticals, Inc. From May 2019 until April 2020, he served as executive Chairman of Curzion Pharmaceuticals, Inc. He served as a Director of Curzion Pharmaceuticals, Inc. since January 2019 until April 2020. He had been an Executive Chairman of Amplyx Pharmaceuticals, Inc. since January 5, 2017 until April 2020. He is Founder of Reneo Pharmaceuticals, Inc. and has been its Executive Chairman since December 2017. He has been a Venture Partner at Pappas Capital, LLC since January 11, 2010 and served as a member of the firm Board of Advisors from 2004 to 2010. He was the Founder, Chairman and Chief Executive Officer at Reneo Pharmaceuticals, Inc. from September 2014 to December 2017 and served as its President. Mr. Grey served as the Chief Executive Officer and President of Amplyx Pharmaceuticals, Inc. from October 2015 to January 4, 2017. He was a Co Founder of Lumena Pharmaceuticals, Inc. and served as its Chief Executive Officer and President since February 2011 until June 2014. He served as the Chief Executive Officer and President of SGX Pharmaceuticals, Inc. since January 2005 and June 2003 respectively. From January 1999 to April 2001, he served as the President and Chief Executive Officer at Lion Bioscience, Inc. He joined Lumena Pharmaceuticals Inc. in 2010 and served as its Assistant Secretary. He served as the Chief Executive Officer and President at Auspex Pharmaceuticals, Inc. between January and September 2009. He served as Executive Vice President and the Chief Business Officer of SGX Pharmaceuticals from April 1, 2001 to June 2003. He served as Executive Director at Lumena Pharmaceuticals Inc. He served as President and Chief Executive Officer of Trega Biosciences, Inc. and served as its Director until 2011. From November 1994 to August 1998, he served as President of BioChem Therapeutic Inc. at Shire Canada Inc. In that role, he was responsible for all company operations including research, development, sales and marketing, finance and human resources. Prior to BioChem Pharma Inc. he served as the Senior Vice President of Corporate Development at Titan Pharmaceuticals Inc. He served as the President and Chief Operating Officer at Ansan Inc. since 1994. From 1974 to 1993, Mr. Grey served in various roles with Glaxo Inc. and Glaxo Holdings PLC, culminating in his position as Vice President of Corporate Development, Head of worldwide business development and Director of International Licensing at GlaxoSmithKline plc. He began his career with Glaxo Inc. and Glaxo Holdings plc, where he served in various roles culminating in his position as Vice President, Corporate Development and Head of International Licensing. He served as Executive Chairman of Ziarco Pharma Ltd. He was an Independent Director of Biomarin Pharmaceutical Inc. since December 14, 2005 until May 25, 2021. He is an Independent Director of Biothera Holding Corp. since July 7, 2015. He was Independent Director of Mirati Therapeutics, Inc. since November 6, 2014 until June 25, 2021. He serves as a Director at Biothera Pharmaceutical and Balance Therapeutics, Inc. He had been a Lead Independent Director of Horizon Therapeutics Public Limited Company (formerly known as Horizon Pharma plc) since August 2012 until October 06, 2023 and served as an Independent Director since September 30, 2011 until October 06, 2023. He serves as a Director of ChemNavigator.com (TM) Inc. Incellico Inc. He serves as an Observer at Ultragenyx. He served as the Chairman of IDM Pharma, Inc. from December 2007 to June 24, 2009. He served as a Member of Board of Advisors at Pappas from 2004 to 2010. He served as a Member of the Board of Directors at RespireRx Pharmaceuticals Inc. He served as Director of SGX Pharmaceuticals, Inc. since September 2001 to 2008. He served as a Director of Selventa, Inc (formerly Genstruct Inc.) since 2011. Mr. Grey served as a Director of IDM Pharma, Inc. from July 1999 to June 24, 2009, Lion Bioscience, Inc. since December 1998, Achillion Pharmaceuticals, Inc. from November 2001 to September 30, 2010, Auspex Pharmaceuticals, Inc. since January 2009 and Cortex Pharmaceuticals, Inc. He served as a Director of Epimmune Inc. since July 1999. He has experience in the pharmaceutical and biotechnology industries. He has graduated in B.S. in Chemistry from University of Nottingham in 1974.

Positions